Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Cone Beam CT for Breast Imaging

18. juni 2013 oppdatert av: Koning Corporation

Cone Beam CT for Breast Imaging: A Pilot Study

The objective of this pilot study is to investigate Cone Beam Computed Tomography Imaging (CBCT), with the primary goal, the accumulation of a body of evidence to provide preliminary data for a future extensive clinical trials.

Studieoversikt

Status

Fullført

Studietype

Observasjonsmessig

Registrering (Faktiske)

76

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New York
      • Rochester, New York, Forente stater, 14620
        • University of Rochester Highland Breast Imaging Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast.

Group II includes forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.

Beskrivelse

Normal Group:

Inclusion Criteria:

  • Are at least 40 years of age of any ethnicity
  • Had a routine mammogram, read as BI-RADS® 0, 1, 2 or 3
  • Will undergo study imaging no later than six months from date of routine mammogram.
  • Is able to undergo informed consent.

Exclusion Criteria:

  • Pregnancy
  • Lactation
  • Patients with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker.
  • Patients who are unable to tolerate study constraints.
  • Patients who have received radiation treatments to the thorax for malignant and nonmalignant conditions, such as (but not limited to)

    • Treatment for enlarged thymus gland as an infant
    • Irradiation for benign breast conditions, including breast inflammation after giving birth
    • Treatment for Hodgkin's disease
  • Patients who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram.
  • Patients who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to)

    • Tuberculosis
    • Severe scoliosis

Diagnostic Group:

Inclusion Criteria:

  • Women who are at least 40 years of age of any ethnicity
  • Have a palpable abnormality detected by Breast Self Exam (BSE), or Clinical Breast Exam (CBE) or have a non-palpable abnormality detected by an imaging modality
  • After diagnostic work-up are categorized as BI-RADS® 4 or 5.
  • Are scheduled for biopsy either by large gauge needle biopsy or excisional biopsy.
  • Will undergo study imaging prior to biopsy and within four weeks of diagnostic work-up.

Exclusion Criteria:

  • Pregnancy
  • Lactation
  • Patients who have already undergone biopsy for the index lesion
  • Patients who are unable or unwilling to undergo biopsy for the lesion of concern
  • Patients with physical limitations that may prohibit the patient from resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker.
  • Patients who are unable to tolerate study constraints.
  • Patients who have received radiation treatments to the thorax or breast area for malignant and nonmalignant conditions, such as (but not limited to)

    • Treatment for enlarged thymus gland as an infant
    • Irradiation for benign breast conditions, including breast inflammation after giving birth
    • Treatment for Hodgkin's disease
  • Patients who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram.
  • Patients who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to)

    • Tuberculosis
    • Severe scoliosis

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Normal Group
In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast. Of these 100, we hope to enroll at least 30 subjects with mammograms read as BI-RADS® 0 and at least 30 read as BI-RADS® 3. The BI-RADS® 0 category refers to patients for whom additional imaging is required after a screening mammogram provided incomplete diagnostic information.
Diagnostic Group
The goals of Group II will be to compare the CBCT study with standard imaging for the diagnosis of breast disease in palpable or non-palpable breast lesions (having a BI-RADS® score of 4 or 5). Forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Image Quality of Cone Beam Breast CT
Tidsramme: 6 years
This study was to evaluate the radiation dose, breast coverage, and image quality of cone-beam breast CT compared with a conventional mammographic examination.
6 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. juli 2006

Primær fullføring (Faktiske)

1. juni 2012

Studiet fullført (Faktiske)

1. juni 2012

Datoer for studieregistrering

Først innsendt

15. juni 2013

Først innsendt som oppfylte QC-kriteriene

18. juni 2013

Først lagt ut (Anslag)

19. juni 2013

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

19. juni 2013

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. juni 2013

Sist bekreftet

1. juni 2013

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • URMC-001

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Brystkreft

3
Abonnere